JNJ · Company research
6 upcoming catalysts · 0 phase 2+ trials on file
View Stock opens Yahoo Finance. Prices and performance charts are provided there.
The FDA is expected to decide in the second half of 2026 (no exact date yet) whether to approve Johnson & Johnson’s IMAAVY (nipocalimab-aahu) for Warm autoimmune hemolytic anemia (wAIHA). Approval clears it for sale in the US; a rejection usually arrives as a letter listing what has to be fixed first.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Johnson & Johnson expects to report results from its Phase 3 study of Milvexian (oral factor XIa inhibitor; J&J/BMS) for Secondary stroke prevention in the second half of 2026 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Johnson & Johnson expects to report results from its Phase 1/2 study of Icotyde (icotrokinra) for Active psoriatic arthritis in the second half of 2026 (no exact date yet). Phase 1/2 is an early study that checks safety and takes a first look at effect.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Johnson & Johnson expects to report results from its Phase 3 study of Inlexzo (TAR-200) for High-risk non-muscle invasive bladder cancer in the second half of 2026 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Johnson & Johnson expects to report results from its Phase 3 study of Caplyta (lumateperone) for Bipolar I mania in the second half of 2026 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Johnson & Johnson expects to report results from its Phase 3 study of Milvexian (oral factor XIa inhibitor; J&J/BMS) for Stroke prevention in atrial fibrillation during 2027 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Johnson & Johnson reported results from its Phase 3 study of TECVAYLI (teclistamab-cqyv) + TALVEY (talquetamab-tgvs) for Relapsed or refractory multiple myeloma, 1-4 prior lines on Jul 23, 2026. The study met its main goal.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Johnson & Johnson presented data on ERLEADA (apalutamide) for High-risk localized or locally advanced prostate cancer at a medical meeting on May 31, 2026. The linked source has the details.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA approved Johnson & Johnson’s TREMFYA (guselkumab) for Active psoriatic arthritis on May 28, 2026. The company can now sell it in that market.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA approved Johnson & Johnson’s CAPLYTA (lumateperone) for Prevention of relapse in schizophrenia on Apr 27, 2026. The company can now sell it in that market.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA approved Johnson & Johnson’s ICOTYDE (icotrokinra) for Moderate-to-severe plaque psoriasis, 12 years and older on Mar 18, 2026. The company can now sell it in that market.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA approved Johnson & Johnson’s TECVAYLI (teclistamab-cqyv) + DARZALEX FASPRO (daratumumab/hyaluronidase-fihj) for Relapsed or refractory multiple myeloma, 1+ prior line on Mar 5, 2026. The company can now sell it in that market.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Explore reported politician transactions and public investor statements connected to JNJ.
View source-linked activity ↗No phase 2+ trials cached for this company.
No recent headlines on file.